WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009143454) COMBINATION ANTITUMOR THERAPY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/143454    International Application No.:    PCT/US2009/045029
Publication Date: 26.11.2009 International Filing Date: 22.05.2009
IPC:
A61K 31/28 (2006.01), A61P 35/00 (2006.01), A61K 31/47 (2006.01), A61K 31/337 (2006.01)
Applicants: KEREOS, INC. [US/US]; 4041 Forest Park Ave. St. Louis, MO 63108 (US) (For All Designated States Except US).
KEENE, Jeffery, L. [US/US]; (US) (For US Only).
RILEY, Dennis, P. [US/US]; (US) (For US Only).
BEARDSLEY, Robert, A. [US/US]; (US) (For US Only)
Inventors: KEENE, Jeffery, L.; (US).
RILEY, Dennis, P.; (US).
BEARDSLEY, Robert, A.; (US)
Agent: SODEY, Benjamin, J.; (US)
Priority Data:
61/055,418 22.05.2008 US
Title (EN) COMBINATION ANTITUMOR THERAPY
(FR) COMBINAISON THÉRAPEUTIQUE ANTICANCÉREUSE
Abstract: front page image
(EN)The present disclosure relates to methods of treating cancers that are responsive to antimetabolite or antimitotic anti-cancer agents. The methods involve the use of at least one anti-cancer agent selected from antimetabolite anti-cancer agents, antimitotic anti-cancer agents, and combinations thereof, and a superoxide dismutase mimetic to potentiate the therapeutic effect of the anti cancer agent(s).
(FR)La présente invention concerne des procédés de traitement de cancers qui sont sensibles à des agents anticancéreux anti-métabolites ou antimitotiques. Les procédés entraînent l’utilisation d’au moins un agent anticancéreux choisi parmi les agents anticancéreux anti-métabolites, les agents anticancéreux antimitotiques et leurs combinaisons, et une substance mimétique de superoxyde dismutase pour potentialiser l’effet thérapeutique du ou des agents anticancéreux.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)